Featured articles
vivoVerse awarded SBIR Phase II grant from the NIEHS
August 5, 2023
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $1.83M Phase II SBIR grant from ...
READ MORE →
vivoVerse cofounders publish single-cell isolation method using femtosecond laser microdissection (fs-LM)
May 3, 2023
vivoVerse cofounders Dr. Adela Ben-Yakar and Dr. Sudip Mondal have published an article in Nature Methods titled “Femtosecond laser microdissection for isolation ...
READ MORE →
Meeting report: A successful and enjoyable time at SOT2023 in Nashville for vivoVerse
April 6, 2023
The vivoVerse team recently attended the 2023 Society of Toxicology (SOT) Annual Meeting. It was a great time networking with ...
READ MORE →
More articles
vivoVerse at the Society of Toxicology Annual Meeting in Nashville
March 2, 2023
The 2023 Society of Toxicology (SOT) Annual Meeting is coming up this month, and we will be attending! The SOT ...
READ MORE →
vivoVerse moves into new HQ
May 5, 2021
vivoVerse (formerly operating as Newormics) has expanded its base of operations into a customized, newly refurbished space in Austin, Texas. ...
READ MORE →
Newormics resumes operations
August 20, 2020
Dear Colleagues, Customers, and Collaborators: At our Newormics location in Austin, TX, we have been allowed to re-open. We have ...
READ MORE →
vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office
August 5, 2020
Patent covers the vivoChip® invention that vivoVerse licensed for use in immobilization of C. elegans for high resolution imaging. AUSTIN, ...
READ MORE →
vivoVerse awarded SBIR Phase II grant from the NIMH
July 8, 2020
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from ...
READ MORE →
COVID-19 UPDATE
March 27, 2020
Dear Customers, Colleagues, and Collaborators: At Newormics, we recognize that combating the spread of this new virus requires a global ...
READ MORE →
Newormics launches new vivoChips for early stage worms
October 14, 2019
Early larval stages of C. elegans (L1 to L3 and Dauer) have always been among the hardest to immobilize and ...
READ MORE →
DDNews features Newormics in their latest issue in a special report on drug screening
August 10, 2019
The research of Newormics is featured in a special report in the July 2019 issue of DDNews in an article ...
READ MORE →
Newormics at the 2019 UK C. elegans meeting
July 30, 2019
Newormics is exhibiting at the 2019 UK C. elegans meeting at Imperial College London on September 16th. Come meet us ...
READ MORE →
Newormics awarded an SBIR Phase I grant from the NIEHS
July 9, 2019
Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project ...
READ MORE →
